New Stock Listing | Montage Technology (06809) debuts on the market with a 57.17% opening surge. The company is the world's largest supplier of memory interconnect chips.
Lanqi Technology (06809) made its debut on the stock market, with each share priced at 106.89 Hong Kong dollars. A total of 65.89 million shares were issued, with 100 shares per lot. The net proceeds amounted to approximately 6.905 billion Hong Kong dollars. As of the time of this release, the stock price has increased by 57.17%, reaching 168 Hong Kong dollars, with a trading volume of 975 million Hong Kong dollars.
Montage Technology (06809) made its debut on the stock market with an initial public offering price of 106.89 Hong Kong dollars per share, issuing a total of 65.89 million shares with a minimum trading unit of 100 shares. The net proceeds from the offering are approximately 6.905 billion Hong Kong dollars. As of the time of publication, the stock has risen by 57.17% to 168 Hong Kong dollars, with a trading volume of 975 million Hong Kong dollars.
According to the prospectus, Montage Technology is a leading global integrated circuit design company without a wafer fab, focusing on providing innovative, reliable, and energy-efficient interconnect solutions for cloud computing and AI infrastructure. The company offers interconnect chips to industry-leading customers, including memory interconnect chips and PCIe/CXL interconnect chips, with applications spanning a wide range of end markets, including data centers, servers, and computers.
According to Frost & Sullivan data, Montage Technology held a global market share of 36.8% for memory interconnect chips in 2024, ranking first in the industry. The company's two main product lines are interconnect chips and Jingdai CPU products, with key customers including CEAC, Micron, Samsung, and SK Hynix.
Related Articles

HK Stock Market Move | SINO BIOPHARM (01177) rose more than 3% with the completion of subject enrollment in Phase III clinical trial of Vituximab Bevacizumab "CLDN18.2 ADC".

HK Stock Market Move | JIAXIN INTL RES (03858) surges more than 6%, expected to turn loss into profit last year, with a maximum profit of up to HK$340 million.

BofA Securities: Maintains "Buy" rating on INNOVENT BIO (01801) with a target price of HK$113.5.
HK Stock Market Move | SINO BIOPHARM (01177) rose more than 3% with the completion of subject enrollment in Phase III clinical trial of Vituximab Bevacizumab "CLDN18.2 ADC".

HK Stock Market Move | JIAXIN INTL RES (03858) surges more than 6%, expected to turn loss into profit last year, with a maximum profit of up to HK$340 million.

BofA Securities: Maintains "Buy" rating on INNOVENT BIO (01801) with a target price of HK$113.5.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


